CELLSPRESSO
LIVE

Serial Number

79223494

Owner

Cell Therapy Limited

Attorney

Melanie Howard

Filing Date

Jul 24, 2017

Add to watchlist:

No watchlists yet
View on USPTO

CELLSPRESSO Trademark

Serial Number: 79223494 • Registration: 5634962

CELLSPRESSO is a trademark filed by Cell Therapy Limited on July 24, 2017. The trademark is classified under Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus). The application is currently registered and active.

Owner Contact Info

Cell Therapy Limited (5 trademarks)

The Maynard Centre

Entity Type: 99

Trademark Details

Filing Date

July 24, 2017

Registration Date

December 25, 2018

Published for Opposition

October 9, 2018

Cancellation Date

July 11, 2025

Goods & Services

Medical and veterinary devices, namely, instruments for the preparation of regenerative cells for implantation into humans and animals for the treatment of damaged and diseased skin, tissue, organs and body parts; disposable cartridges for medical and veterinary devices, namely, instruments for the preparation of regenerative cells for implantation into humans and animals for the treatment of damaged and diseased skin, tissue, organs and body parts; portable medical and veterinary apparatus, namely, instruments for the preparation of regenerative cells for implantation into humans and animals for the treatment of damaged and diseased skin, tissue, organs and body parts; surgical, medical, and veterinary apparatus, devices, and instruments for use in implanting regenerative cells into humans and animals to treat damaged and diseased skin, tissue, organs and body parts; surgical, medical, and veterinary apparatus, devices, and instruments for use in cell therapy and regenerative medicine; medical and veterinary devices, namely, applicators to implant regenerative cells into humans and animals for the treatment of damaged and diseased skin, tissue, organs and body parts; sample preparation devices for medical diagnostic use; apparatus for the regeneration of stem cells for medical purposes; component parts and fittings for all of the aforesaid

Pharmaceutical preparations for the treatment of diseased skin, tissue, organs and body parts in the nature of treatment for viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases; veterinary pharmaceutical preparations for the treatment of diseased skin, tissue, organs and body parts in the nature of treatment for viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases; pharmaceutical preparations and substances for the treatment of damaged skin and tissue, namely, tissue regenerative pharmaceutical preparations; cellular medicines, namely, stem cells for medical or veterinary use; reagents for medical or veterinary use; clinical medical and veterinary reagents; medical and veterinary diagnostic reagents; reagents for medical and veterinary diagnosis and medical and veterinary diagnostic research; chemical reagents for testing aqueous solutions for medical and veterinary purposes; reagents for use in biological processing for medical and veterinary purposes; media for biological and bacteriological cultures for medical and veterinary use; non-aqueous solvents for use in tests for medical and veterinary purposes; aqueous solutions for use in tests for medical and veterinary purposes; non-aqueous culture media for medical and veterinary use; chemicals preparations, namely, buffer solutions for use in tests for medical and veterinary purposes; chemicals, namely, surfactants for use in tests for medical and veterinary purposes

Filing History

TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
Mar 11, 2026 INTR
CANCELLED SECTION 71
Jul 11, 2025 C71T
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Dec 25, 2023 REM3
NEW REPRESENTATIVE AT IB RECEIVED
Dec 4, 2021 NREP
NEW REPRESENTATIVE AT IB RECEIVED
Oct 25, 2019 NREP
FINAL DECISION TRANSACTION PROCESSED BY IB
Apr 26, 2019 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Apr 5, 2019 FICS
FINAL DISPOSITION PROCESSED
Apr 5, 2019 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Mar 25, 2019 FICR
REGISTERED-PRINCIPAL REGISTER
Dec 25, 2018 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Oct 9, 2018 NPUB
PUBLISHED FOR OPPOSITION
Oct 9, 2018 PUBO
NOTIFICATION PROCESSED BY IB
Oct 6, 2018 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Sep 19, 2018 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Sep 19, 2018 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Sep 19, 2018 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Aug 28, 2018 CNSA
EXAMINER'S AMENDMENT ENTERED
Aug 3, 2018 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Aug 3, 2018 GNEN
EXAMINERS AMENDMENT E-MAILED
Aug 3, 2018 GNEA
EXAMINERS AMENDMENT -WRITTEN
Aug 3, 2018 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 19, 2018 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 18, 2018 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 18, 2018 TROA
REFUSAL PROCESSED BY IB
Feb 16, 2018 RFNP
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jan 26, 2018 RFCS
REFUSAL PROCESSED BY MPU
Jan 26, 2018 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jan 19, 2018 RFCR
NON-FINAL ACTION WRITTEN
Jan 18, 2018 CNRT
APPLICATION FILING RECEIPT MAILED
Dec 30, 2017 MAFR
ASSIGNED TO EXAMINER
Dec 26, 2017 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Dec 26, 2017 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Dec 21, 2017 REPR